Previous 10 | Next 10 |
SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the closing of its underwritten public offering of 5,175,000 shares of its common stock at a public offer...
SAN FRANCISCO, March 09, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that Arthur Sands, M.D., Ph.D., Nurix’s chief executive officer, will participate and pre...
TransCode Therapeutics has filed to raise $29 million in an IPO. The firm is developing treatments for metastatic cancer and other conditions. RNAZ has produced impressive results in preclinical mice studies. For further details see: TransCode Therapeutics Starts $29 Mil...
4 Health Care Stocks To Consider Buying In March Health care is one of the most important sectors in the world today. They are one of the largest and most complex sectors, with a broad range of companies that sell medical products and services. Investors are watching the health care...
Gainers: Second Sight Medical Products EYES +151%, XTL Biopharmaceuticals (XTLB) +42%, Nurix Therapeutics (NRIX) +9%, Auris Medical Holding (EARS) +5%, Anchiano Therapeutics (ANCN) +5%.Losers: Evofem Biosciences EVFM -34%, T2 Biosystems (...
Nurix Therapeutics (NRIX) has priced its upsized public offering of 4.5M common shares at $31.00/share (from 4M).Expected gross proceeds are $139.5M.Underwriters' over-allotment is an additional 675k shares.Closing date is March 9.Previously (March 2): Nurix Therapeutics launches 4M stock off...
SAN FRANCISCO, March 04, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced the pricing of its underwritten public offering of 4,500,000 shares of its common stock at a public offer...
Nurix Therapeutics (NRIX) trades 1.9% down after hours on commencing an underwritten public offering of 4M shares; underwriters granted 30-day option to purchase up to an additional 600K shares.Offer size, terms not yet disclosed. For further details see: Nurix Therapeutics la...
SAN FRANCISCO, March 02, 2021 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. All of the shar...
Nurix Therapeutics (NRIX): Q4 GAAP EPS of -$0.51 beats by $0.03.Revenue of $6.69M (+259.7% Y/Y) beats by $2.75M.Press Release For further details see: Nurix Therapeutics EPS beats by $0.03, beats on revenue
News, Short Squeeze, Breakout and More Instantly...
Nurix Therapeutics Inc. Company Name:
NRIX Stock Symbol:
NASDAQ Market:
Nurix Therapeutics Inc. Website:
2024-07-12 17:15:01 ET Oppenheimer analyst issues OUTPERFORM recommendation for NRIX on July 12, 2024 03:19PM ET. The previous analyst recommendation was Outperform. NRIX was trading at $23.82 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
Presented positive clinical data at the European Hematology Association Congress supporting a potential best-in-class profile for NX-5948 for the treatment of CLL Strengthened leadership with appointment of Paula G. O’Connor, M.D., as chief medical officer and Pasit Phiasivongsa,...
SAN FRANCISCO, July 08, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Arthur T. Sands, M.D., Ph.D., pr...